Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

118.64 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus 
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Uncover top picks in undervalued blue-chip stocks, unfairly punished yet consistently delivering strong operational results 
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
Merck & Co Unusual Options Activity
Via Benzinga
Insights Into Merck &amp; Co's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... 
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
These are the blue-chip stocks to buy as they represent fundamentally strong companies with robust free cash flow visibility 
Via InvestorPlace
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
Via Benzinga
Exposures COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best and worst performers. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Merck Stock On Monday?
Merck secures exclusive global rights to develop and commercialize opevesostat (MK-5684/ODM-208) for hormone-dependent cancers. Orion is eligible for milestone payments up to $1.63 billion and tiered... 
Via Benzinga
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
With Washington likely having to take steps to cut the U.S. deficit within the next few years, here are three sectors at risk. 
Via InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
These are the undervalued blue-chip stocks to buy as they represent companies with a steady growth and robust cash flow outlook. 
Via InvestorPlace
What's Going On With Merck Stock On Friday?
The CDC's Advisory Committee on Immunization Practices recommends Merck's Capvaxive for adults 65+ and certain at-risk individuals 19-64. Merck also announces CHMP's positive recommendation for... 
Via Benzinga
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
The FDA rejected Merck's Daiichi Sankyo-partnered antibody drug conjugate. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
This Recent FDA Approval Is Bad News for Pfizer
One of the pharma giant's top-selling products is about to face some intense competition. 
Via The Motley Fool
Exposures Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
Via Benzinga
Exposures Product Safety
These Are The Best Dow Jones Stocks Of 2024 Thus Far
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... 
Via Benzinga
7 Dividend Stocks to Buy Now for Enhanced Returns
These dividend stocks can round out a diversified portfolio - or anchor a value-based income investment strategy. 
Via InvestorPlace
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
Via Benzinga
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Forget Nvidia: Prominent Billionaires Are Selling It in Favor of These 7 Top-Notch Stocks
More than a half-dozen of Wall Street's most-successful billionaire investors dumped shares of Nvidia during the March-ended quarter and made these seven stocks their top buys. 
Via The Motley Fool
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
These are the undervalued pharma stocks and represent companies with a deep research pipeline, that provides sustained growth visibility. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.